ResMed Statistics
Total Valuation
ResMed has a market cap or net worth of $37.39 billion. The enterprise value is $36.86 billion.
| Market Cap | 37.39B |
| Enterprise Value | 36.86B |
Important Dates
The last earnings date was Thursday, October 30, 2025, after market close.
| Earnings Date | Oct 30, 2025 |
| Ex-Dividend Date | Nov 13, 2025 |
Share Statistics
ResMed has 145.75 million shares outstanding. The number of shares has decreased by -0.28% in one year.
| Current Share Class | 145.75M |
| Shares Outstanding | 145.75M |
| Shares Change (YoY) | -0.28% |
| Shares Change (QoQ) | -0.09% |
| Owned by Insiders (%) | 0.53% |
| Owned by Institutions (%) | 69.03% |
| Float | 144.84M |
Valuation Ratios
The trailing PE ratio is 26.26 and the forward PE ratio is 22.91. ResMed's PEG ratio is 1.67.
| PE Ratio | 26.26 |
| Forward PE | 22.91 |
| PS Ratio | 7.15 |
| Forward PS | 6.50 |
| PB Ratio | 6.12 |
| P/TBV Ratio | 14.22 |
| P/FCF Ratio | 21.15 |
| P/OCF Ratio | 19.85 |
| PEG Ratio | 1.67 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.01, with an EV/FCF ratio of 20.84.
| EV / Earnings | 25.63 |
| EV / Sales | 7.01 |
| EV / EBITDA | 19.01 |
| EV / EBIT | 20.91 |
| EV / FCF | 20.84 |
Financial Position
The company has a current ratio of 2.89, with a Debt / Equity ratio of 0.14.
| Current Ratio | 2.89 |
| Quick Ratio | 1.87 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | 0.43 |
| Debt / FCF | 0.48 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 25.41% and return on invested capital (ROIC) is 16.93%.
| Return on Equity (ROE) | 25.41% |
| Return on Assets (ROA) | 14.18% |
| Return on Invested Capital (ROIC) | 16.93% |
| Return on Capital Employed (ROCE) | 24.99% |
| Revenue Per Employee | $526,794 |
| Profits Per Employee | $144,079 |
| Employee Count | 9,980 |
| Asset Turnover | 0.68 |
| Inventory Turnover | 2.03 |
Taxes
In the past 12 months, ResMed has paid $302.96 million in taxes.
| Income Tax | 302.96M |
| Effective Tax Rate | 17.40% |
Stock Price Statistics
The stock price has increased by +4.36% in the last 52 weeks. The beta is 0.87, so ResMed's price volatility has been lower than the market average.
| Beta (5Y) | 0.87 |
| 52-Week Price Change | +4.36% |
| 50-Day Moving Average | 259.77 |
| 200-Day Moving Average | 252.77 |
| Relative Strength Index (RSI) | 54.76 |
| Average Volume (20 Days) | 993,809 |
Short Selling Information
The latest short interest is 10.65 million, so 7.31% of the outstanding shares have been sold short.
| Short Interest | 10.65M |
| Short Previous Month | 8.96M |
| Short % of Shares Out | 7.31% |
| Short % of Float | 7.35% |
| Short Ratio (days to cover) | 8.27 |
Income Statement
In the last 12 months, ResMed had revenue of $5.26 billion and earned $1.44 billion in profits. Earnings per share was $9.77.
| Revenue | 5.26B |
| Gross Profit | 3.19B |
| Operating Income | 1.76B |
| Pretax Income | 1.74B |
| Net Income | 1.44B |
| EBITDA | 1.94B |
| EBIT | 1.76B |
| Earnings Per Share (EPS) | $9.77 |
Balance Sheet
The company has $1.38 billion in cash and $846.35 million in debt, giving a net cash position of $537.50 million or $3.69 per share.
| Cash & Cash Equivalents | 1.38B |
| Total Debt | 846.35M |
| Net Cash | 537.50M |
| Net Cash Per Share | $3.69 |
| Equity (Book Value) | 6.12B |
| Book Value Per Share | 41.94 |
| Working Capital | 2.37B |
Cash Flow
In the last 12 months, operating cash flow was $1.88 billion and capital expenditures -$114.99 million, giving a free cash flow of $1.77 billion.
| Operating Cash Flow | 1.88B |
| Capital Expenditures | -114.99M |
| Free Cash Flow | 1.77B |
| FCF Per Share | $12.13 |
Margins
Gross margin is 60.69%, with operating and profit margins of 33.52% and 27.35%.
| Gross Margin | 60.69% |
| Operating Margin | 33.52% |
| Pretax Margin | 33.11% |
| Profit Margin | 27.35% |
| EBITDA Margin | 36.87% |
| EBIT Margin | 33.52% |
| FCF Margin | 33.64% |
Dividends & Yields
This stock pays an annual dividend of $2.40, which amounts to a dividend yield of 0.94%.
| Dividend Per Share | $2.40 |
| Dividend Yield | 0.94% |
| Dividend Growth (YoY) | 11.88% |
| Years of Dividend Growth | 13 |
| Payout Ratio | 23.13% |
| Buyback Yield | 0.28% |
| Shareholder Yield | 1.22% |
| Earnings Yield | 3.85% |
| FCF Yield | 4.73% |
Analyst Forecast
The average price target for ResMed is $292.27, which is 13.92% higher than the current price. The consensus rating is "Buy".
| Price Target | $292.27 |
| Price Target Difference | 13.92% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | 8.34% |
| EPS Growth Forecast (5Y) | 10.48% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 31, 2010. It was a forward split with a ratio of 2:1.
| Last Split Date | Aug 31, 2010 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
ResMed has an Altman Z-Score of 12.67 and a Piotroski F-Score of 6.
| Altman Z-Score | 12.67 |
| Piotroski F-Score | 6 |